Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Fig. 1

Effect of palbociclib and venetoclax on PDX models of R/R MCL. Legend: Synergistic effect of CDK4/6 inhibition with palbociclib and BCL2 blockage with venetoclax on a panel of 4 PDX models of R/R MCL. X-axis shows days from initiation of therapy. Y-axis shows calculated tumor volume of PDX tumors (means ± standard deviations)

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us